PE-22-28

PE-22-28 is a synthetic peptide analog derived from spadin, an endogenous fragment of the sortilin propeptide. It is characterized by its ability to selectively interact with the TREK-1 potassium channel. In laboratory settings, PE-22-28 is examined as a research tool for probing TREK-1 function and related signaling cascades. Material is supplied strictly for in-vitro and controlled laboratory research use only.

PE-22-28 is studied for selective blockade of the TREK-1 (KCNK2) two-pore-domain potassium channel. Channel inhibition is investigated for its influence on neuronal excitability and downstream modulation of serotonergic pathways. Research models explore how TREK-1 blockade may alter membrane potential dynamics and second-messenger systems linked to synaptic plasticity. These mechanistic studies are conducted in cellular and tissue preparations under controlled experimental conditions.

Investigations of PE-22-28 focus on TREK-1 channel inhibition and associated effects on serotonergic signaling. Additional research areas include neurogenesis markers and indicators of synaptic plasticity within cell-based and animal models of depressive-like phenotypes. Scientists use the peptide to examine rapid-onset molecular responses following TREK-1 blockade. All work remains confined to non-clinical laboratory systems.

Laboratory studies report that PE-22-28 produces TREK-1 inhibition consistent with rapid antidepressant-like behavioral readouts in validated animal models. Parallel cell-culture work has documented changes in signaling pathways related to neuronal survival and plasticity after channel blockade. Findings are limited to preclinical experimental systems and do not extend to clinical interpretation. Results continue to inform structure-activity relationships among spadin-derived peptides.

PE-22-28 is intended solely for qualified laboratory personnel conducting in-vitro or approved animal-model research. Standard peptide-handling practices apply, including appropriate storage, reconstitution, and documentation of experimental conditions. Researchers should verify purity and concentration for each lot prior to use. The compound is not for human or animal consumption and carries no approved therapeutic designation.